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Intraoperative Ceforanide Pharmacokinetics and Protein Binding
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The pharmacokinetics and protein binding of ceforanide were studied in 15 patients undergoing cholecys-
tectomies. Each patient received ceforanide (20 mg/kg) intravenously on arrival in the operating room, after
which serial blood samples were collected during the elimination phase for determination of total and free
ceforanide concentrations in the serum. A high-pressure liquid chromatography assay was used, with a
centrifugal filtration system for free-drug determinations. Serum concentration data for each individual were
subjected to linear regression to determine the elimination rate constants (total and free drug), volumes of
distribution, and systemic clearances. The mean elimination rate constants were 0.41 and 0.50 h-1 for total and
free ceforanide, respectively. The mean percentage of ceforanide bound to serum protein was 87.9%. The
relationship of the free ceforanide concentration to the total concentration appeared to be linear. The data were
fit to double-reciprocal and half-reciprocal relationships with good agreement, showing one binding site and an
association constant range of 1.6 x i07 to 1.9 x 107 at these in vivo concentrations. The mean volume of
distribution and mean systemic clearance of total drug were 100 ml/kg and 45.9 ml/min per 1.73 in2,
respectively. Ceforanide consistently produced higher intraoperative total drug concentrations compared with
those of cefazolin and cefoxitin from similar studies.
The basic principle underlying the use of prophylactic
antimicrobial agents is that the agent should be available
during the time of potential bacterial contamination (2, 9).
For surgical prophylaxis, this critical period begins with the
initial incision and continues, in most cases, until the wound
is closed. Optimal use of antimicrobial agents for surgical
prophylaxis requires the agent to be present during this
entire interval (2).
The availability of an antimicrobial agent at the site of
potential contamination, the surgical wound, is related to the
presence of antimicrobial agents in serum. Many factors
affect tissue penetration by antimicrobial agents. When
serum concentrations of beta-lactam antimicrobial agents
are minimal, tissue concentrations are usually low. The
transfer of an antibiotic into peripheral tissues is directly
related to the area under the concentration versus the time
curve for free drug (1). This area is partially determined by
the free fraction of drug circulating in serum.
We previously investigated the intraoperative concentra-
tions of cefazolin and cefoxitin (3). Considerable differences
were observed in total drug concentrations throughout the
operations. Cefazolin concentrations were two to three
times higher than those of cefoxitin. Cefoxitin, the agent
with a shorter elimination half-life, demonstrated that more
frequent intraoperative readministration is needed.
Antimicrobial agents with relatively long elimination half-
lives may be advantageous since they could provide ade-
quate concentrations in serum throughout the surgical pro-
cedure. Ceforanide was chosen for this study because of its
relatively long elimination half-life of 3.0 h (7, 10-12). The
objective of this study was to determine the intraoperative
pharmacokinetics and in vivo protein binding of ceforanide
after preoperative, intravenous administration.
* Corresponding author.
MATERIALS AND METHODS
Subject selection. Hospitalized adult patients (18 to 70
years old) scheduled to undergo cholecystectomies were
screened for study entry. The study protocol was approved
by the Human Assurance Committee at the Medical College
of Georgia, and written informed consent was obtained from
each patient. All patients weighed between 60 and 90 kg, and
none were more than 30% over ideal body weight. Evidence
of renal or hepatic disease (creatinine clearance less than 60
ml/min and serum transaminase or alkaline phosphatase that
was twice normal) was cause for patient exclusion. Neither
antimicrobial agents nor probenicid was given for at least 1
week before the study. Serum creatinine, albumin, and total
proteins were also determined, preoperatively, within 72 h.
Albumin was determined by a colorimetric technique (SMA-
II; Technicon Instruments Corp., Inc., Terrytown, N.Y.).
The assay has demonstrated coefficients of variation from
2.9 to 3.4% at concentrations of 2 to 3.3 g/dl.
Drug administration. All patients received ceforanide (20
mg/kg) intravenously over 10 min on arrival in the operating
room (drug supplied by Bristol Laboratories, lot 82L428). A
second 1-g intravenous dose was given 12 h later.
Blood sampling. For each patient at least three intraoper-
ative blood samples were collected (at initial incision, 1 h
postincision, and wound closure). For operations lasting
longer than 2 h, additional intraoperative blood samples
were collected hourly. Serum was immediately separated
from blood cells and stored at -25°C until analyzed.
Drug analysis. A high-pressure liquid chromatographic
technique was developed with a Waters U6k injector and
440A detector set at 254 nm. A C18, 25-cm column (Altech,
Chicago, Ill.) was used with a flow rate of 2.0 ml/min of
mobile phase (ratio of 0.1 M sodium acetate buffer [pH
4.0]/methanol, 90:10). Samples were prepared as follows. To
0.5 ml of patient plasma, 50 [ul of sulfacetamide solution (1
mg/ml) was added as an internal standard; then 0.1 ml of 6%
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TABLE 1. Patient and pharmacokinetic data
Total ceforanide Free ceforanide
Patient Age (years) Wt (kg) Ceforanidedose (g) Kei (h 1) l/2" (h) V (ml/kg) CL (ml/min K&I (h-') t412 (h)
1 62 60 1.2 0.31 2.26 101 33.5 0.62 1.12
2 35 65 1.3 0.79 0.88 67 60.8 0.54 1.29
3 31 60 1.2 0.43 1.63 104 48.0 0.41 1.68
4 43 78 1.6 0.35 1.96 101 41.1 0.38 1.84
5 22 85 1.7 0.42 1.66 112 59.9 0.62 1.12
6 60 66 1.3 0.20 3.48 108 26.3 0.17 4.11
7 32 79 1.6 0.38 1.83 111 55.9 0.49 1.41
8 27 64 1.3 0.49 1.42 113 59.4 0.44 1.57
9 24 77 1.5 0.50 1.38 94 57.4 0.70 0.99
10 44 90 1.8 0.27 2.56 103 33.0 0.40 1.72
11 34 65 1.3 0.35 1.97 100 39.5 0.54 1.29
12 63 61 1.2 0.20 3.47 107 24.0 0.23 2.96
13 26 70 1.4 0.50 1.39 83 46.4 0.71 0.97
14 22 86 1.7 0.34 2.04 115 49.6 0.32 2.14
15 19 57 1.2 0.61 1.13 84 53.5 0.87 0.80
Mean (+SD) 36.3 (+14.9) 70.9 (+10.7) 1.4 (+0.2) 0.41 (+0.16) 1.94 (+0.76) 100 (+13) 45.9 (±12.4) 0.50 (±0.19) 1.67 (±0.87)
a 112, Half-life.
trichloroacetic acid was added to precipitate proteins, and
the solution was vortexed for 1 min. Acetonitrile (1 ml) was
then added, and the mixture was centrifuged for 10 min at
2,500 x g. The supernatant was transferred to a tube
containing 5 ml of methylene chloride, vortexed for 1 min,
and then shaken for 10 min. After centrifugation, 100 pI of
the aqueous-phase solution was injected into the high-pres-
sure liquid chromatography apparatus.
A standard curve for ceforanide-free acid was prepared by
using final concentrations of 0, 2, 4, 8, 12, 16, 20, 30, 40, 60,
80, 100, and 120 ,ug of plasma per ml, with a resultant r of
0.999. The coefficients of variation were 1.7% at 2 ,ug/ml and
1.4% at 20 p.g/ml.
Free ceforanide was separated from bound ceforanide by
using a centrifugal filtration system (Amicon micropartition
system with YMT membranes). Serum was placed in the
filtration system and centrifuged at 3,000 rpm for 20 min.
Then 0.2 ml of filtrate was collected and mixed with the
internal standard (20 ,u1), and the sample was injected
directly into the high-pressure liquid chromatography col-
umn under the conditions above. The YMT membrane was
tested for any loss of ceforanide that may have been caused
by absorption on the membrane during the filtration process.
Six aqueous solutions of ceforanide with concentrations
varying from 5 to 100 ,ug/ml were used in duplicate, and the
mean change in concentration from nonfiltered solution was
from +1.43% at 5 p.g/ml to -0.71% at 100 jig/ml with a high
value of 4.02% at 20 jig/ml.
Data analysis. For each subject, data for total and free
ceforanide concentrations in serum versus time were sub-
jected to linear regression analysis to determine individual
intraoperative elimination rate constants (Kel) assuming a
one-compartment model. Differences in Kel for total and free
ceforanide were tested by the Wilcoxon Rank Sum test (4).
From individual linear regression, concentrations were pro-jected for standardized postinfusion times that corresponded
to intraoperative events. Specifically, projected concentra-
tions were determined for 30, 150, and 210 min postinfusion,
corresponding to the appropriate time of initial incision and
of closure for a 2- or 3-h operation, respectively.
The volume of distribution (V) was calculated for each
individual from the back extrapolated total ceforanide con-
centration at time zero. Ceforanide systemic clearance (CL)
was determined as the product of Kel and V.
Calculation of the binding parameters was performed in
the following manner. First, the concentration of bound
ceforanide in serum at every time point was calculated by
subtracting the free concentration of ceforanide in serum
from the total concentration. The number of moles of
ceforanide bound per mole of albumin (r) was calculated by
the following equation. r = [ceforanide concentration (,ug/ml)
bound in serum]/[MW (x 106) of ceforanide]/[albumin con-
centration (g/100 ml) in serum]/[MW (x 100) of albumin],
(equation 1), where the molecular weight (MW) of cefora-
nide is 519 and the MW for albumin is 67,500. r can be
related to the serum concentration of free moles of cefora-
nide (A) to yield the following familiar equation:
nK(A)
r= K
I + K(A) (2)
where n is the number of binding sites available on albumin
and K is the association constant (15). Since all of the
ceforanide concentrations were within a relatively narrow
range, it was a preliminary assumption that there was only
one principle class of binding sites available. Equation 2 can
be transformed in at least three different ways to obtain a
linear relationship between r and A. The double-reciprocal
relationship (6) results as follows:
lr = (llnK)1/A + lln
The half-reciprocal relationship (8) is given as follows:
Alr = (1/n)A + lInK
(3)
(4)
The Scatchard (9) relationship can be expressed as follows:
rlA = Kn - Kr (5)
Parameter estimates from equations 3, 4, and 5 were ob-
tained by linear regression with a weighted least-squares
method (lly) (8).
RESULTS
The ages and weights of 15 patients who completed the
investigation (3 male, 12 female) are given in Table 1. The
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FIG. 1. Total and free ceforanide concentrations in serum versus
time postinfusion.
mean dose of ceforanide administered was 1,420 ± 210 mg
(range, 1,200 to 1,800 mg). The operations averaged 1.76 ±
0.8 h from incision to wound closure. Serum concentrations
with the linear regression lines for total or free drug are
shown in Fig. 1. These data imply that the Ke1s for total and
free ceforanide are approximately equivalent. However,
from linear regression of the data for each individual, the
mean Kels for total and free ceforanide were 0.41 ± 0.16 and
0.50 ± 0.19 h-1, respectively (Table 1). The Kel for free drug
was significantly greater than that for total drug (P < 0.05
[Wilcoxon Rank Sum test]) (4) as indicated in Fig. 2. The
mean percentage of ceforanide bound to serum proteins was
87.9%. The mean V and mean CL of total drug were 100
ml/kg and 45.9 ml/min per 1.73 mi2, respectively. The rela-
tionship of the free concentration of ceforanide in serum to
total ceforanide was linear over the range of drug concen-
trations used in this study.
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FIG. 2. Comparison of individual ceforanide elimination rate
constants for free and total ceforanide. The broken line represents
unity.
TABLE 2. Mean projected serum concentrations for total and
free ceforanide
Time post-drug Corresponding Total drug Free drug
infusion (min) intraoperative (g/ml SD) (,ug/ml ± SD)infusionm) event
30 Initial incision 165.0 ± 16.5 21.1 + 3.9
150 Wound closure 71.1 + 28.2 8.3 ± 3.6
(2-h operation)
210 Wound closure 52.4 ± 22.3 5.5 + 3.6
(3-h operation)
Concentrations of total and free ceforanide were projected
from the linear regression data of each individual for times
corresponding to key intraoperative events, as described
previously. These results are summarized in Table 2.
The number of binding sites and the association constant
for the ceforanide-albumin in vivo binding interaction are
given in Table 3. The results indicated that, at the therapeu-
tic concentrations of ceforanide, a single binding site existed
on albumin for this drug. The parameter values based on the
half-reciprocal relationship are in close agreement with the
parameter values obtained via the double-reciprocal method.
The standard errors of the mean with a 95% confidence
interval for the slope were 15 and 26% of the slope, respec-
tively, for double-reciprocal and half-reciprocal relation-
ships. The values obtained from the Scatchard relationship
were different; however, the Scatchard relationship failed to
provide a reasonable fit to the data. A plot of the binding
data based on the double-reciprocal relationship is shown in
Fig. 3.
DISCUSSION
Throughout the surgical procedures, ceforanide consist-
ently produced high total drug concentrations in these pa-
tients relative to the values reported for cefazolin and
cefoxitin by similar methods (3). It appears that a single
preoperative dose of ceforanide would provide a sufficient
intraoperative antimicrobial concentration even for long
operations (over 4 h).
The mean elimination half-life determined in this study is
somewhat shorter than previously reported for normal vol-
unteers (1.9 h versus 2.6 to 3.0 h, respectively) although CL
is similar (7, 10-12). The intraoperative serum protein bind-
ing for ceforanide is slightly greater than that reported for
normal volunteers (87.9 versus 81%) (12). Differences in
reported parameters may have resulted from the conditions
during the surgical procedures. No other reports are cur-
rently available in the literature describing intraoperative
ceforanide pharmacokinetics other than in open-heart sur-
gery with a cardiopulmonary bypass (5, 10). The stress and
trauma imposed by the surgical incision as well as the
administration of a multitude of medications preoperatively
TABLE 3. In vivo protein binding data
n of
Method binding K (M-') Slope Intercept F
sites
Double 1.03 1.65 x 107 5.8 x 10-8 0.96 175.7"
reciprocal
Half 0.91 1.97 x 107 1.09 5.5 x 10-8 65.6"
reciprocal
Scatchard 3.51 3.4 x 106 -3.4 x 106 1.27 x 107 3.1
F, Variance ratio.
Significant (P < 0.001).
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FIG. 3. Plot of the double-reciprocal relationship where r equals
the number of moles of ceforanide bound per mole of albumin andA
equals the moles of free ceforanide in serum.
and intraoperatively (e.g., anesthetic gases, anticholinergic
agents, and opiate derivatives) may affect drug pharmacoki-
netics, but differences between the study group and reported
data from normal volunteers are not dramatic.
In this investigation, attempts were made to determine
ceforanide binding parameters. Low binding ratios were
present and used to calculate the in vivo binding parameters.
The value of 1.6 x 107 to 1.9 x 107 for the binding constant
is high, and in relation to the in vitro binding of other
antibacterial agents, such a large value has not been hereto-
fore reported (14). Estimates of binding parameters in vivo
have not been routinely examined until recently. The rele-
vance of the binding parameters reported here should be-
come more apparent as further in vivo protein binding
studies are reported for other cephalosporins or under other
conditions.
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